[1]
|
Zhang, Y.D., Tian, J. and Xiao, F. (2021) B Cell-Activating Factor and Its Targeted Therapy in Autoimmune Diseases. Cytokine & Growth Factor Reviews, 64, 57-70.
|
[2]
|
李会婷, 王丹丹, 熬慧娟, 毕慧. B细胞激活因子在免疫性血小板减少症发病机制中的研究现状[J]. 国际输血及血液病血杂志, 2023, 46(1): 19-25.
|
[3]
|
Bowman, S.J., Fox, R., Dörner, T., et al. (2022) Safety and Efficacy of Subcutaneous Ianalumab (VAY736) in Patients with Primary Sjögren’s Syndrome: A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Dose-Finding Trial. Lancet, 399, l61-171. https://doi.org/10.1016/S0140-6736(21)02251-0
|
[4]
|
Wang, Q.T., Ma, Y.K., Huang, B., et al. (2011) Effect of rhTACI-Ig Fusion Protein on Antigen-Specific T Cell Responses from Keyhole Limpet Haemocyanin Challenged Mice. Molecular Immunology, 49, 380-386.
|
[5]
|
Lai, K.L.Q., King, H.K., Zheng, B.J., et al. (2008) Local BAFF Gene Si-lencing Suppresses Th17-Cell Generation and Ameliorates Autoimmune Arthritis. Proceedings of the National Academy of Sciences of the United States of America, 105, 14993-14998. https://doi.org/10.1073/pnas.0806044105
|
[6]
|
Scapini, P., Hu, Y., Chu, C.L., et al. (2010) Myeloid Cells, BAFF, and IFN-γ Establish an Inflammatory Loop That Exacerbates Autoimmunity in Lyn-Deficient Mice. Journal of Experi-mental Medicine, 207, 1757-1773.
https://doi.org/10.1084/jem.20100086
|
[7]
|
Меrrіll, J.Т., Ѕhаnаhаn, W.R., Ѕсhеіnbеrg, M., еt аl. (2018) Рhаѕе Ш Trial Results with Blisibimod, a Selective Inhibitor of B-Cellactivating Factor, in Subjects with Systemic Lupus Erythe-matosus (SLE): Results from a Randomised, Double-Blind, Placebo-Controlled Trial. Annals of the Rheumatic Diseases, 77, 883-889.
https://doi.org/10.1136/annrheumdis-2018-213032
|
[8]
|
Gross, J.A., Johnston, J., Mudri, S., et al. (2000) TACI and BCMA Are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease. Nature, 404, 995-999. https://doi.org/10.1038/35010115
|
[9]
|
葛风梅, 王学彬. B细胞激活因子在风湿性疾病中的研究进展[J]. 滨州医学院学报, 2017, 40(1): 62-64, 68.
|
[10]
|
Thorn, M., Lewis, R.H., Mumbey-Wafula, A., et al. (2010) BAFF Overex-pression Promotes Anti-dsDNA B-Cell Maturation and Antibody Secretion. Cellular Immunology, 261, 9-22. https://doi.org/10.1016/j.cellimm.2009.10.004
|
[11]
|
Dörner, T., Posch, M.G., Li, Y., et al. (2019) Treatment of Primary Sjögren’s Syndrome with Ianalumab (VA Y736) Targeting B-Cells by BAFF Receptor l Blockade Coupled with Enhanced, Antibody-Dependent Cellular Cytotoxicity. Annals of the Rheumatic Diseases, 78, 641-647. https://doi.org/10.1136/annrheumdis-2018-214720
|
[12]
|
崔清彦, 颉迎新, 王文欣, 等. 免疫性血小板减少症发病机制的研究进展[J]. 山东医药, 2020, 60(4): 102-105.
|
[13]
|
黄炜祺, 周咏明. 原发免疫性血小板减少症的免疫机制研究进展[J]. 中国实验血液学杂志, 2019, 27(4): 339-342.
|
[14]
|
文瑞婷, 杨志刚, 聂丽容, 等. B细胞活化因子及调节性T细胞在免疫性血小板减少症发病中的作用[J]. 广东医科大学学报, 2017, 35(4): 353-355.
|
[15]
|
隋晓. Th9细胞及IL-9在原发免疫性血小板减少症中的作用研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2020.
|
[16]
|
吕俊廷, 梁海燕, 姜朝晖. BAFF在原发免疫性血小板减少症发病中的作用[J]. 临床医学工程, 2018, 25(6): 781-782.
|
[17]
|
朱晓璐, 冯非儿, 王谦明, 王辰骢, 张晓辉. B细胞激活因子在免疫性血小板减少性症发病机制中的作用[J]. 中华医学杂志, 2014, 94(48): 3868-3870.
|
[18]
|
Khalifa, K.A.E., El-Hawy, M.A., Zeid, H.M.A. and El-Kholy, R.M. (2023) Expression of B-Cell Activating Factor in Pediatric Patients with Immune Thrombocytopenia: A Single Institutional Series and Review of Literature. Journal of Immunoassay & Immunochemistry, 44, 41-55. https://doi.org/10.1080/15321819.2022.2114363
|
[19]
|
Wang, Y., Jia, X., Zhou, L., et al. (2021) Increased let-7b-5p Is Associated with Enhanced BAFF-R Expression and B Cell Survival in Immune Thrombocytopenia. International Immunopharmacology, 93, Article ID: 107393.
https://doi.org/10.1016/j.intimp.2021.107393
|
[20]
|
张颖, 付妤. B细胞激活因子在慢性炎症性疾病中研究进展[J]. 医学研究杂志, 2021, 50(12): 145-148.
|
[21]
|
陈玙, 王梅芳, 陈剑芳, 等. 成人原发免疫性血小板减少症161例疗效及预后的影响因素分析[J]. 中华全科医师杂志, 2018, 17(10): 794-797.
|